Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Hydrolases
Reexamination Certificate
2001-04-25
2004-07-27
Weber, Jon P. (Department: 1651)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Hydrolases
C435S212000
Reexamination Certificate
active
06767539
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to medical science particularly the treatment of viral hemorrhagic fever with protein C.
BACKGROUND OF THE INVENTION
Protein C is a vitamin K dependent serine protease and naturally occurring anticoagulant that plays a role in the regulation of hemostasis by inactivating Factors Va and VIIIa in the coagulation cascade. Human protein C circulates as a 2-chain zymogen, but functions at the endothelial and platelet surface following conversion to activated protein C (aPC) by limited proteolysis with thrombin in complex with the cell surface membrane protein, thrombomodulin.
In conjunction with other proteins, aPC functions as perhaps the most important down-regulator of blood coagulation resulting in protection against thrombosis. In addition to its anti-coagulation functions, aPC has anti-inflammatory effects through its inhibition of cytokine generation (e.g. TNF and IL-1) and also exerts profibrinolytic properties that facilitate clot lysis. Thus, the protein C enzyme system represents a major physiological mechanism of anti-coagulation, anti-inflammation, and fibrinolysis.
Viral hemorrhagic fever is a clinical syndrome associated with significant mortality. Without exception, hemorrhagic fever viruses are enveloped RNA viruses that belong to four viral families: Arenaviridae [Junin, Machupo, Lassa fever], Bunyaviridae [Crimean-Congo hemorrhagic fever, Rift Valley fever, Hantaan and related viruses], Filoviridae [Ebola, Marburg] and Flaviviridae [Dengue, Yellow fever, Omsk hemorrhagic fever, Kyasanur Forest disease], [Cosgriff, T. M.,
Reviews of Infectious Diseases
11(4): S672-S688, 1989]. These agents produce a wide spectrum of disease severity, but the most extreme manifestations include circulatory instability, increased vascular permeability, and diffuse hemorrhage [Lacy, et al.
Advances in Pediatric Infectious Diseases,
12:21-53, 1997].
The underlying mechanism of the bleeding in the hemorrhagic fevers is complex. Possible factors include thrombocytopenia alone, or thrombocytopenia associated with disseminated intravascular coagulation (DIC). Central to the mechanism may well be endothelial cell dysfunction, which has profound implications for both platelets and coagulation. Another possible factor is a decrease in levels of coagulation factors in plasma as the result of either increased consumption or impaired synthesis. Increased consumption occurs in DIC, while impaired synthesis is the likely consequence of liver injury. Liver involvement is a universal occurrence in viral hemorrhagic fever. For example, in Yellow fever, Rift Valley fever and Crimean-Congo hemorrhagic fever, the temporal association of hemorrhage with sever hepatic dysfunction is evident.
Viruses alter hemostasis in two general ways. The first is through direct effect on cellular functions, and the second is through activation of immune and inflammatory pathways. Both mechanisms may lead to variable degrees of cellular injury, including cell death. Activation of coagulation pathways is an important part of immune and inflammatory reactions and accounts for the fibrin deposition that sometimes is observed in these reactions.
Thrombocytopenia is a universal occurrence in viral hemorrhagic fevers. For example, in dengue hemorrhagic fever both changes suggestive of decreased thrombopoiesis and of increased platelet consumption has been determined. This is also the case in hemorrhagic fever with renal syndrome (HFRS) caused by Hantaan and related viruses. Other mechanisms for increased platelet destruction in viral infections include direct interaction of platelets with viruses, DIC, and endothelial injury.
In Ebola and Marburg hemorrhagic fevers, generalized hemorrhages are found in most organs. Focal necrosis without significant inflammation is also widely seen, especially in the lungs, liver, kidneys, and lymphoid organs. DIC is common.
Currently, there is no effective therapy to treat viral hemorrhagic fever. In the absence of viral-specific chemotherapy, management is primarily supportive. Therefore, a need exists for a safe, effective therapy of patients with viral hemorrhagic fever.
The present invention is the first to describe the treatment of viral hemorrhagic fever with protein C. Protein C, with its anticoagulant, anti-inflammatory, and profibrinolytic activities, is useful for the treatment of the hypercoagulable state or protein C deficiency that occurs in viral hemorrhagic fever patients.
SUMMARY OF THE INVENTION
The present invention provides a method of treating a patient suffering from viral hemorrhagic fever which comprises, administering to said patient a pharmaceutically effective amount of protein C.
The present invention further provides a method of treating viral hemorrhagic fever in a patient in need thereof, which comprises administering to said patient a pharmaceutically effective amount of activated protein C such that an activated protein C plasma level of about 2 ng/ml to about 300 ng/ml is achieved.
REFERENCES:
patent: 4775624 (1988-10-01), Bang et al.
patent: 4981952 (1991-01-01), Yan
patent: 4992373 (1991-02-01), Bang et al.
patent: 5453373 (1995-09-01), Gerlitz et al.
patent: 5478558 (1995-12-01), Eibl et al.
patent: 5516650 (1996-05-01), Foster et al.
patent: 5550036 (1996-08-01), Grinnell
patent: 0 445 939 (1991-09-01), None
patent: WO 97/20043 (1997-06-01), None
Faust et al, “Dysfunction of Endothelial Protein C Activation in Severe Meningococcal Sepsis”(Aug. 9, 2001) N. Engl. J. Med., 345(6), 408-416.*
EMEA Committee For Proprietary Medicinal Products European Public Assessment Report (EPAR) Ceprotin Abstract—CPMP/1383/01 (2001).*
Cosgriff, et al., “Viruses and Hemostasis”,Reviews of Infectious Diseases, 11(4): S672-S688.
Lacy, et al., “Viral Hemorrhagic Fevers”,Advances in Pediatric Infectious Diseases, 12:21-53, 1997.
Grinnell, et al., “Trans-Activated Expression of Fully Gamma-Carboxylated Recombinant Human Protein C, An Antithrombotic Factor”, Bio/Technology, 5:1189-1192, 1987.
Takazoe, K. et al., “Association of Plasma Levels of Activated Protein C with Recanalization of the Infarct-Related Coronary Artery After Thrombolytic Therapy in Acute Myocardial Infarction”Thrombosis Researchvol. 95, 37-47 (1999).
Granger, C. , et al., “Rebound Increase in Thrombin Generation and Activity After Cessation of Intravenous Heparin In patients With Acute Coronary Syndromes”Circulation, vol. 91, No 7 1929-1935 (1995).
Mesters, R. et al., “Factor VIIa and Antithrombin III Activity During Severe Sepsis and Septic Shock in Neutropenic Patients”Blood, vol. 88, No. 3 881-886 (1996).
Mesters, R., et al., “Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications”Crit Care Med, vol. 28 No. 7, 2209-2216 (2000).
Kleijn, E., et al., “Activation of protein following infusion of protein C concetrate in children with sever meningococcal sepsis and purpura fulminans: A randomized, double-blinded, placebo-controlled, dose finding study”Crit Care Med, vol. 31, No. 6, 1839-1847 (2003).
Gerson, W. et al. “Severe Acquired Protein C Deficiency in Purpura Fulminans Associated with Disseminated Intravascular Coagulation: Treatment with Protein C Concentrate”Pediatrics, vol. 91, No. 2, 418-422 (1993).
Rivard, G. et al., “Treatment of purpura fulminans in meningococcemia with protein C concentrate”J. of Pediatrics, vol. 126, No 4, 646-652 (1995).
Rintala, R., et al., “Protein C in the treatment of coagulopathy in meningococcal disease”Crit. Care Med., vol. 26, No. 5, 965-968 (1998).
Fisher Charles Jack
Yan Sau-Chi Betty
Barrett Brian P.
Eli Lilly and Company
Hostettler Danica
LaGrandeur Thomas E.
Weber Jon P.
LandOfFree
Method of treating viral hemorrhagic fever does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating viral hemorrhagic fever, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating viral hemorrhagic fever will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3191570